s
s
s
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug omalizumab (Xolair) using our range of ready-made anti-idiotypic and complex-specific antibodies.
Table 1. Antibodies Specific to Omalizumab and Omalizumab-hIgE Complex.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Omalizumab Inhibitory Type 1 |
HCA236 |
AbD20669 |
Fab-FH1 |
1.1 |
PK bridging ELISA |
|
HCA235 HCA235P |
AbD20669_hIgG1 |
Human IgG1 HRP |
1.1 |
PK bridging ELISA ADA control |
||
Omalizumab-hIgE Complex Specific Type 3 |
HCA238 |
AbD20760 |
Fab-FH1 |
0.58 |
PK ELISA antigen capture format |
|
HCA237 HCA237P |
AbD20760_hIgG1 |
Human IgG1 HRP |
0.58 |
PK ELISA antigen capture format |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK and His-6-tags
Type 1 anti-omalizumab antibodies inhibit the binding of the drug omalizumab to its target, human immunoglobulin E (hIgE). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The Type 3 antibody specifically recognizes the drug-target complex, detecting omalizumab only when it is bound to hIgE. It is suitable as a detection antibody in a PK antigen capture assay as an alternative assay format to the bridging ELISA.
Fig. 1. Omalizumab PK bridging ELISA using antibodies HCA236 and HCA235P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Omalizumab PK antigen capture ELISA using antibody HCA237P.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, Ig format (blue), labeled with HRP.
Fig. 3. Omalizumab ADA bridging ELISA using antibody HCA235. Addition of human serum changes the binding curve due to the presence of endogenous IgE, which interferes with the assay.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.